These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
572 related items for PubMed ID: 19450720
1. Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. Gradman AH, Papademetriou V. Am Heart J; 2009 Jun; 157(6 Suppl):S17-23. PubMed ID: 19450720 [Abstract] [Full Text] [Related]
2. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications. Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A. Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491 [Abstract] [Full Text] [Related]
5. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. Azadpour M, Lamas GA. Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434 [Abstract] [Full Text] [Related]
6. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy. Dhaliwal AS, Bredikis A, Habib G, Carabello BA, Ramasubbu K, Bozkurt B. Am J Cardiol; 2008 Nov 15; 102(10):1356-60. PubMed ID: 18993155 [Abstract] [Full Text] [Related]
7. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Prisant LM. Am J Med; 2008 Aug 15; 121(8 Suppl):S8-15. PubMed ID: 18638617 [Abstract] [Full Text] [Related]
10. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ. Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527 [No Abstract] [Full Text] [Related]
11. The therapeutic role of RAS blockade in chronic heart failure. Werner CM, Böhm M. Ther Adv Cardiovasc Dis; 2008 Jun 16; 2(3):167-77. PubMed ID: 19124420 [Abstract] [Full Text] [Related]
12. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now? Böhm M. Am J Cardiol; 2007 Aug 06; 100(3A):38J-44J. PubMed ID: 17666197 [Abstract] [Full Text] [Related]
13. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Kjeldsen SE, Lyle PA, Tershakovec AM, Devereux RB, Oparil S, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Wedel H. Expert Opin Emerg Drugs; 2005 Nov 06; 10(4):729-45. PubMed ID: 16262560 [Abstract] [Full Text] [Related]
15. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Makkar KM, Sanoski CA, Spinler SA. Pharmacotherapy; 2009 Jan 06; 29(1):31-48. PubMed ID: 19113795 [Abstract] [Full Text] [Related]
18. Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study. Peltier M, Houpe D, Cohen-Solal A, Béguin M, Levy F, Tribouilloy C. Int J Cardiol; 2007 Jun 12; 118(3):363-9. PubMed ID: 17049391 [Abstract] [Full Text] [Related]